Engineered immune cells take on tough leukemia in early trial
NCT ID NCT06307054
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new treatment made from a person's own immune cells, called CLL-1 CAR-NK cells, for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The study aims to see if the treatment is safe and tolerable, and to get an early look at how well it works. About 24 participants aged 18 to 70 will receive the cells and be closely monitored for side effects and leukemia response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, 200080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cell 'Bridge' offers new hope for tough leukemia
- New pill aims to keep leukemia away after transplant
- Experimental cocktail aims to beat back tough leukemia
- New pill shows promise for tough blood cancers in early trial
- Engineered immune cells offer new hope for Hard-to-Treat leukemia
- New drug cocktail aims to tackle tough leukemia